What To Know
- Additionally, he has completed a fellowship in interventional cardiology at Emory School of Medicine and became the director of the Andreas Gruentzig Cardiovascular Center from 1994 -1999 at Emory.
- Artrya's core solution is Salix Coronary Anatomy – a fast and effective AI-based technology capable of analysing cardiac CT scans to illustrate a unique combination of coronary artery disease biomarkers, including components of high-risk plaque.
Artrya Limited, Australian medical technology company, creator of the AI-based Artrya Salix, a solution that supports physicians in the diagnosis of coronary artery disease, today announced the appointment of US Cardiologist Nicolas Chronos, MD, to its Clinical Advisory Board. He will join Board Chair Dr. Jacque J. Sokolov in promoting key medical research partnerships and oversee US based research in support of Artrya’s US market entry.
Artrya’s core solution is Salix Coronary Anatomy – a fast and effective AI-based technology capable of analysing cardiac CT scans to illustrate a unique combination of coronary artery disease biomarkers, including components of high-risk plaque.
Artrya Managing Director and Co-Founder John Barrington AM commented: “We are delighted to welcome Dr Chronos, whose strong cardiology research background will be of tremendous value to the company. He brings decades of experience and solid research to the Clinical Advisory Board as we prepare to enter the US market.”
Artrya Salix supports clinicians in the diagnosis of coronary artery disease by highlighting the presence and extent of atherosclerotic plaque on a 3D heart image. A comprehensive overview is produced within 15 minutes to assist in developing a patient report, aiding personalized and optimal treatment.
“It’s an honor to join Artrya’s world-class team as we begin to introduce the US to this advanced method of cardiac diagnosis,” said Chronos. “We’ll be working with key opinion leaders and subject matter experts to demonstrate how our new technology will help diagnose and treat heart disease.”
Chronos is President and Managing Partner of Cardiology Care Clinics of Eatonton, Georgia. He served as the Clinical and Strategy Executive Vice-President of Endtronix, a data-driven heart failure management solution that detects worsening heart failure earlier to guide therapeutic interventions. He currently is a principal investigator for the Atlanta Institute for Medical Research. He was an adjunct partner at Essex Woodlands Health Ventures in the Medtech group from 2004-2012. He was the President and CEO of SJTRI, Atlanta, the largest non-profit, translational research institute in the USA from 2002-2012.
Chronos received his Bachelor of Science Honors Human Biology degree from Surrey University, London, England and a Bachelor of Medicine and Surgery from Royal Free Hospital School of Medicine in London. He served his general medical rotation residency at Northwick Park Hospital, London and performed his cardiology fellowship at Royal Free Hospital. He finished research fellowships in cardiology at Royal Brompton National Heart and Lung Hospital in London and Emory University School of Medicine. Additionally, he has completed a fellowship in interventional cardiology at Emory School of Medicine and became the director of the Andreas Gruentzig Cardiovascular Center from 1994 -1999 at Emory.
The announcement follows the January appointment of renowned healthcare executive Dr. Jacque J. Sokolov as Chair of Artrya’s Clinical Advisory Board. Most recently Ted Schwab and Jory Tremblay have been appointed as Co-CEOs of Artrya USA and will head up the company’s entry into the US market. The two will guide Artrya’s launch in the US, including the development of its US strategy, clinical research partnerships and go to market approach. For further information and opportunities to be a clinical partner contact: Jory Tremblay, jory.tremblay@artrya.com or Ted Schwab, ted.schwab@artrya.com.